Preliminary In Vivo Evaluation of a Nanofiltered Factor IX Concentrate

• References

• 1 Mannucci PM. Viral safety of plasma-derived and recombinant products used in the management of hemophilia A and B. Haemophilia 1995; 1 Suppl (Suppl. 01) 14-21
• 2 Bumouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX:C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-232
• 3 Bumouf-Radosevich M, Appourchaux P, Huart JJ, Bumouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX ?and factor XI concentrates. Vox Sang 1994; 67: 132-138
• 4 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati RC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606-611
• 5 Goudemand J, Marey A, Caron C, Wibaut B, Mizon P. Clinical efficacy of a highly purified SD-treated IX concentrate prepared by conventional chroma-tography. Transf Med 1993; 3: 299-305
• 6 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-2545